Published: July 2015

The Mylan-Teva merger is a healthcare disaster for consumers

A proposed merger of the two largest U.S. generic drug makers drew opposition from seven consumer groups. Advocates asked antitrust enforcers at the Federal Trade Commission to stop Teva Pharmaceutical Industries proposal to purchase Mylan, saying it would lead to higher prices for consumers and more drug shortages.

In a letter to the Federal Trade Commission, Consumer Action and its coalition advocates urge the agency to oppose the merger of two pharmaceutical giants, saying a takeover would exacerbate generic drug shortages and reduce competition within the pharmaceutical industry. Israel-based Teva has said it wants to buy Netherlands-based Mylan for about $40 billion, if Mylan drops a $34 billion hostile takeover bid for Irish drugmaker Perrigo Co.

Lead Organization

Consumers Union

Other Organizations

Consumers Union | Consumer Federation of America | U.S. PIRG | Public Citizen | Consumer Action | Consumer Watchdog | Community Catalyst | National Center for Health Research

More Information

For more information, please visit Consumers Union's website.

Download PDF

The Mylan-Teva merger is a healthcare disaster for consumers   (LettertoFTCreMylan-TevaMerger.pdf)




Quick Menu

Facebook FTwitter T